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Abstract
Background: Monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have been approved for
the treatment of patients with metastatic colorectal carcinoma (mCRC) that do not carry KRAS mutations. Therefore, KRAS
testing has become mandatory to chose the most appropriate therapy for these patients.
Methodology/Principal Findings: In order to guarantee the possibility for mCRC patients to receive an high quality KRAS
testing in every Italian region, the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pathology and
Cytopathology -Italian division of the International Academy of Pathology (SIAPEC-IAP) started a program to improve KRAS
testing. AIOM and SIAPEC identified a large panel of Italian medical oncologists, pathologists and molecular biologists that
outlined guidelines for KRAS testing in mCRC patients. These guidelines include specific information on the target patient
population, the biological material for molecular analysis, the extraction of DNA, and the methods for the mutational
analysis that are summarized in this paper. Following the publication of the guidelines, the scientific societies started an
external quality assessment scheme for KRAS testing. Five CRC specimens with known KRAS mutation status were sent to
the 59 centers that participated to the program. The samples were validated by three referral laboratories. The participating
laboratories were allowed to use their own preferred method for DNA extraction and mutational analysis and were asked to
report the results within 4 weeks. The limit to pass the quality assessment was set at 100% of true responses. In the first
round, only two centers did not pass (3%). The two centers were offered to participate to a second round and both centers
failed again to pass.
Conclusions: The results of this first Italian quality assessment for KRAS testing suggest that KRAS mutational analysis is
performed with good quality in the majority of Italian centers.
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Introduction
Mutations of the KRAS gene occur in approximately 40% of
colorectal carcinomas (CRC), and about 90% of these mutations
affect codons 12 and 13 [1]. KRAS mutations occur relatively
early in colorectal tumor progression, and therefore they are
usually present in the majority of the transformed cells within a
KRAS mutant tumor [2]. The presence of the mutations in a
restricted and well defined region of the gene and the occurrence
of the mutations in an high percentage of tumor cells facilitates the
detection of KRAS mutations in tumor tissues.
A number of studies have demonstrated that anti-EGFR
monoclonal antibodies are active only in metastatic CRC (mCRC)
patients that do not carry mutations of the KRAS gene. In
particular, analysis of patients treated in phase II and III
randomized clinical trials with anti-EGFR antibodies alone or in
combination with chemotherapy, in any line of treatment, have
shown that anti-EGFR agents increase the response rate and
improve the progression free survival (PFS) only in mCRC patients
that do not carry KRAS mutations at codons 12 and 13
[3,4,5,6,7,8,9]. More recently, addition of cetuximab to FOLFIRI
in patients with KRAS wild-type disease was also found to result in
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significant improvements in overall survival (OS) [10]. Following
these results, the European Medical Agency (EMEA) approved in
2009 the use of the anti-EGFR antibodies cetuximab and
panitumumab only in patients with mCRC carrying a wild type
KRAS gene. As a matter of fact, this was the first approval of a drug
for a solid tumor based on a genetic test.
Following the approval of anti-EGFR antibodies for KRAS wild
type CRC patients, KRAS testing has become mandatory to
choose the most appropriate therapeutic strategy in mCRC. In
this respect, both false-negative and false-positive results are
potentially harmful for patients. In fact, false positive findings will
deprive the patients of the possibility to benefit of an active
treatment. On the other hand, false-negative patients might be
treated with a drug that is not active. In addition, recent findings
suggest that administration of an anti-EGFR monoclonal antibody
in combination with a regimen containing oxaliplatin to patients
with a KRAS mutant tumor might significantly reduce progression
free survival [7,9].
The introduction of a mutational assay in clinical practice has
raised the issue to ensure a rapid and high quality KRAS testing to
all patients. Recommendations for KRAS testing in mCRC
patients were released by the European Society of Pathology (ESP)
in 2008 [11]. A recent survey in 14 countries in Europe, Latin
America and Asia showed that the frequency of KRAS testing in
patients with mCRC increased from 3% in 2008 to 47% in 2009
and 69% in 2010 [12]. In particular, the 2010 survey revealed that
test results were available within 15 days for 82%, 51% and 98%
of the tested patients in the European, Latin American and Asian
regions, respectively.
In Italy few surgical pathology laboratories were equipped to
run molecular diagnostics at the time KRAS testing became
mandatory for the prescription of anti-EGFR antibodies in mCRC
patients. In order to guarantee the possibility for mCRC patients
to receive an high quality KRAS testing in every Italian region, the
Italian Association of Medical Oncology (AIOM) and the Italian
Society of Pathology and Cytopathology -Italian division of the
International Academy of Pathology (SIAPEC-IAP) started a
program to improve KRAS testing. This program was based on
the development of guidelines for KRAS mutational analysis in
mCRC patients. Following the publication of the guidelines, the
scientific societies started an external quality assessment scheme
for KRAS testing, in order to evaluate the effects of guidelines on
molecular diagnostic for KRAS mutations in Italy. This paper
describes the development of this program that started in 2008 and
was completed in 2010.
Methods
Methodology for guidelines
AIOM and SIAPEC-IAP identified a large panel of Italian
medical oncologists, pathologists and molecular biologists that met
for the first time in September 2008. Following the meeting,
guidelines for KRAS testing were written by a restricted steering
committee and submitted to the panel of experts for their
comments. By the end of January 2009, the document was
integrated with all the comments. The guidelines were published
on the websites of both AIOM and SIAPEC-IAP in February
2009 (www.aiom.it, 2009; www.siapec.it, 2009). A revised version
of the guidelines was prepared in 2010 and it was published in
November 2010 (www.aiom.it, 2010; www.siapec.it, 2010).
External quality assessment scheme
AIOM and SIAPEC-IAP identified a board of experts who were
assigned to organize the external quality assessment scheme and that
are the co-authors of this paper. Within the group three referral
surgical pathology departments (Department of Human Pathology and
Oncology, University of Florence; Department of Pathology, Univer-
sity-Foundation, Chieti; Division of Pathology, Ospedale Niguarda Ca’
Granda, Milan) and three referral laboratories (Department of
Pathology, University-Foundation, Chieti; Institute for Cancer Re-
search and Treatment, University of Turin, Tuino; Pharmacogenomic
Laboratory, CROM, Avellino, Italy) were identified.
Formalin-fixed paraffin embedded (FFPE) colon carcinoma
specimens were collected at the referral surgical pathology
departments. For each specimen, 5m-thick slides were sent to the
three referral laboratories for mutational analysis in a blind
fashion. The referral laboratories analyzed the samples by using
two different methods: direct sequencing of the PCR product by
using in-house validated methods, and Real Time PCR with the
Therascreen KRAS kit (DxS, Manchester, UK) according to
manufacturer’s instructions.
Slides for each center participating to the quality assessment
were obtained from the selected samples. The scheme included
two rounds: the laboratories that failed the first round had the
chance to register for a second round.
Results
The Italian guidelines for the mutational analysis of the KRAS
gene in CRC prepared by AIOM and SIAPEC-IAP were the
result of an open discussion that involved the Italian scientific
CRC community. The guidelines are available at the websites of
AIOM and SIAPEC-IAP (www.aiom.it; www.siapec.it) and the
main points are summarized in the following paragraphs.
Target patient population
Mutational screening of the KRAS gene should be performed in
patients with mCRC for which treatment with anti-EGFR
monoclonal antibodies might be indicated. Mutational analysis
can be performed by using tissue from either the primary tumor or
a metastatic site, since high concordance has been observed
between primary tumors and metastases for KRAS mutations in
the majority of the studies published up to now [13,14,15].
Biological material for molecular analysis
Either frozen or FFPE tissues can be used for mutational
analysis. Usually, testing for clinical purpose is performed with
FFPE tissues. The primary pathologist plays a fundamental role in
KRAS testing, since he has the responsibility to choose the most
appropriate specimen for mutational analysis (Table 1). In
particular, tissues for KRAS genotyping should contain an
adequate percentage of tumor cells to avoid false negative results.
However, this limit depends on the method that is used for
mutational analysis [1]. International guidelines suggest that the
specimen should contain at least 70% of tumor cells if a low
sensitivity technique such as direct sequencing of the PCR product
is used [11]. Based on the experience of our group in the last two
years, we recently set this limit to 50%. In any case, the specimen
should contain at least 100 tumor cells.
If the tumor specimen has a lower percentage of tumor cells, the
pathologist is requested to manually dissect the tissue in order to
isolate the region that contains the highest percentage of tumor
cells. Laser microdissection can also be used. However, this
approach is not feasible as a routine clinical procedure.
DNA extraction
DNA can be extracted from FFPE tissues by using different
methods. Kits for DNA extraction from different sources including
Italian Quality Assessment for KRAS Testing
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FFPE tissues are commercially available, and are usually based on
the use of chromatographic columns. The use of kits has several
advantages, including the shorter time necessary for the extraction
and an easier standardization of the procedure. The quality and
the quantity of the extracted DNA should be assessed by
spectrophotometric analysis and/or agarose gel electrophoresis.
Mutational analysis
Different methods can be used to assess the mutational status of
KRAS in CRC patients (Table 2). These methods should be able
to detect the seven most common mutations of the KRAS gene in
codons 12 and 13: G35A (G12D), G35T (G12V), G34T (G12C),
G34A (G12S), G35C (G12A), G34C (G12R), and G38A (G13D)
[1]. In fact, only these KRAS mutations were investigated in the
clinical trials that led to the registration of anti-EGFR monoclonal
antibodies in metastatic CRC patients with wild type KRAS.
Direct sequencing of the PCR product represents the golden
standard for mutational analysis. PCR primers should be designed
to amplify codons 12 and 13 of the KRAS gene. PCR reactions
should be prepared in a laminar flow hood by using gloves and
filter tips, and areas for pre- and post-PCR analysis should be kept
separated (Table 3).
An adequate amount of genomic DNA (80–100 ng) should be
amplified, in order to avoid artifacts that have been described to
occur when a low quantity of input DNA in the PCR reaction is
used. Positive and negative controls are required for each PCR
amplification. We also suggest to use for sequencing at least 40–
50 ng of PCR product. The products of two different PCR
reactions should be sequenced in forward and reverse in order to
obtain 3–4 sequences for each sample. A mutation can be called
when present in at least two different sequences (forward and
reverse) obtained from independent PCR amplifications.
One of the major limit of PCR/sequencing is the relatively low
sensitivity (Table 2). More sensitive techniques are available to
detect KRAS mutations. The Therascreen kit is a Real Time
PCR-based assay the uses ARMS primers and Scorpion probes to
detect the above listed seven most common mutations of KRAS in
codons 12 and 13. This method is highly sensitive being able to
detect KRAS mutations when they represent as low as 1% of the
total DNA.
Pyrosequencing and, more recently, methods based on
differential amplification of mutant DNA and hybridization with
probes immobilized on a membrane are quite sensitive assays to
detect KRAS mutations. However, comparative studies in large
cohorts of patients with these techniques are not available yet.
The general recommendations for the preparation of PCR
reactions for these latter methods are similar to PCR/sequencing.
The quantity of DNA to be amplified, the conditions of
amplification and the interpretation of the results are described
in details by the manufacturers.
External Quality Assessment scheme
Following the release of guidelines, AIOM and SIAPEC-IAP
decided to start an external quality assessment scheme for KRAS
testing in CRC that was mainly focused on genotyping. Italian
laboratories that perform mutational analysis of KRAS were
invited to participate to the quality assessment program. Sixty
centers registered to the program at a dedicated website (www.
krasquality.it). One of the centers declined, 59 centers participated
to the program that started on March 15, 2009.
Three referral surgical pathologies selected 16 primary FFPE
CRC with adequate content of tumor cells (.70%) (Table 4). The
mutational status of the 16 samples was assessed in the three
referral laboratories by using different techniques (Table 4). A
good agreement on KRAS mutational status of the selected
specimens was found among the three laboratories. A discordant
result was found only for sample N. 6 in which PCR/sequencing
detected only the G35C mutation, whereas Therascreen identified
also a G34A mutant clone (Table 4). The DCt for the G34A
mutation was significantly higher as compared with the G35C,
and this might explain the lack of detection with PCR/sequencing
that has a lower sensitivity as compared with Therascreen
(Table 2). A meeting was held in February 2009 to select 10
samples, 5 for the first round and 5 for the second round. Samples
for which a total concordance on the mutational status was found
between the three referral laboratories, and from which a good
yield of genomic DNA was obtained, were selected for the quality
assessment scheme (Table 4). For each round 3 mutant and 2 wild
type cases were chosen.
Five 5m-thick slides for each sample were sent to the laboratories
participating to the quality control. A random code, different for
Table 1. Characteristics of the specimens for KRAS
mutational analysis.
Tissues from the primary tumor or a metastatic site can be used
Testing for clinical purpose is usually performed with FFPE tissues
The specimen should contain at least 50% of tumor cells if a low sensitivity
technique is used
The region with the highest percentage of tumor cells can be isolated with
manual dissection
Laser microdissection should be limited to selected cases
doi:10.1371/journal.pone.0029146.t001
Table 2. Sensitivity of the main methods used for KRAS
genotyping in Italy.
Method Sensitivity*
PCR/sequencing 10–25
Pyrosequencing 5–10
PCR/RFLP 10
PCR with Stop primers and reverse dot blot 1–5
ARMS/scorpion probes (Therascreen) 1
*lower level of mutant DNA that can be detected, expressed as % of total DNA.
doi:10.1371/journal.pone.0029146.t002
Table 3. Recommendations for PCR/sequencing analysis.
PCR primers should amplify codons 12 and 13 of the KRAS gene
PCR reactions should be prepared in a laminar flow hood by using gloves and
filter tips
Areas for pre- and post-PCR analysis must be kept separated
80–100 ng of genomic DNA should be amplified
Include positive and negative controls for each PCR amplification
The products of two different PCR reactions should be sequenced in forward
and reverse
A mutation can be called when present in two different sequences (forward and
reverse)
doi:10.1371/journal.pone.0029146.t003
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each center, was automatically assigned to the samples by an
application of the website, in order to avoid exchange of
information between the laboratories. The laboratories were given
4 weeks to complete the analyses and to submit the results through
the KRASquality website and by fax. The laboratories were asked
to submit only the results of genotyping.
All the centers submitted the results within the established
deadline. Of the 59 centers, 48 (81.3%) performed the mutational
analysis by using PCR sequencing, 5 (8.5%) with pyrosequencing,
3 (5.1%) with Real Time PCR (Therascreen kit), 2 (3.4%) with
RFLP analysis and 1 (1.7%) with the KRAS strip assay (Figure 1).
The limit to pass the quality assessment was set at 100% of true
responses. In the first round, only two centers failed to pass (3%).
Both centers did not manage to extract enough genomic DNA for
the mutational analyses. The samples from which the laboratories
failed to extract DNA were different, suggesting that this
phenomenon was not related to the quality of the specimens that
they received. According to the guidelines of the scheme, the two
centers were offered to participate to a second round. Again, both
centers failed to pass the second round due to inability to extract
genomic DNA from FFPE tissues.
The list of the centers that passed the external quality
assessment scheme was published on the websites of AIOM and
SIAPEC (www.aiom.it, 2009; www.siapec.it, 2009).
Discussion
The approval of anti-EGFR agents for the treatment of mCRC
patients that do not carry KRASmutations represented a significant
innovation for medical oncology. In fact, this was the first approval
of an anti-tumor agent for a solid tumor based on a mutational
analysis. More recently, the EGFR tyrosine kinase inhibitor gefitinib
has been approved for treatment of non-small-cell lung cancer
(NSCLC) patients that carry mutations of the EGFR gene. It is likely
that in the next future other drugs will require the assessment of the
mutational status of predictive biomarkers, represented either by the
target of the drug or by signaling proteins that can affect the efficacy
of the anti-tumor agent.
Different methods can be used to detect KRAS mutations in
CRC specimens, and each of them has advantages and limits [1].
The approval of anti-EGFR agents for CRC without mutations of
KRAS has not been linked by the regulatory agencies to a specific
mutational assay. In Italy approximately 18.000 new cases of
mCRC per year are expected. The Italian health system is
organized on a regional basis and, with few exceptions, the
majority of Italian regions did not set a limit in the number of
laboratories that can run mutational analysis. Therefore, several
different centers are offering KRAS testing in the different areas of
the country, and a wide array of methods are employed for such
analysis. For these reasons, external quality assessment is
mandatory to assure that mutational testing is performed with
high quality in every Italian center that provides this service.
Table 4. Mutational status of the samples used for the quality assessment.
Sample N.
Laboratory 1
PCR/Sequencing
Laboratory 2
PCR/Sequencing
Laboratory 3
Therascreen Sample code*
1 G35A (G12D) G35A (G12D) G35A (G12D) A1
2 G38A (G13D) G38A (G13D) G38A (G13D) A2
3 Wild type Wild type Wild type -
4 G35T (G12V) G35T (G12V) G35T (G12V) A3
5 Wild type Wild type Wild type A4
6 G35C (G12A) G35C (G12A) G35C (G12A) -
G34A (G12S)
7 Wild type Wild type Wild type -
8 Wild type Wild type Wild type A5
9 G35A (G12D) G35A (G12D) G35A (G12D) B1
10 G34A (G12S) G34A (G12S) G34A (G12S) B2
11 G35A (G12D) G35A (G12D) G35A (G12D) B3
12 Wild type Wild type Wild type -
13 Wild type Wild type Wild type B4
14 Wild type Wild type Wild type -
15 Wild type Wild type Wild type B5
16 G35A (G12D) G35A (G12D) G35A (G12D) -
* = samples chosen for the external quality assessment program: A1–A5: samples for the first round; B1–B5: samples for the second round.
doi:10.1371/journal.pone.0029146.t004
Figure 1. Methods used for KRAS genotyping by the centers
participating to the Italian Quality assessment scheme.
doi:10.1371/journal.pone.0029146.g001
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The first external quality assessment scheme for KARS
mutation testing was exclusively focused on genotyping. In fact,
the aim of this first scheme was to assess the rate of false positive
and negative results. The results of the scheme were exciting. The
first success of the program was that the majority of the Italian
centers that perform KRAS mutational analysis accepted to
participate to the external quality assessment. This underlines the
need of the testing laboratories to confirm the quality of their
analysis through an external, independent and recognized system
of evaluation. In addition, the rate of laboratories that passed was
exceptionally high, since only 2 centers out of 59 failed. Although
the number of samples used was limited (n.5), the threshold to pass
the scheme was extremely high, since only the centers that
assigned the correct genotype to all the samples passed.
Nevertheless, a larger number of samples will be used in the next
external quality assessment that is planned for 2012. The two
laboratories that did not succeed did not manage to extract
enough genomic DNA from FFPE tissues. Interestingly, both
laboratories were not surgical pathologies, but genetics units that
were use to run tests on blood or fresh tissues. Therefore, we
hypothesize that they might have used procedures or kits for
genomic DNA extraction that are not specific for FFPE specimens.
The list of the centers that passed the external quality
assessment was published on the websites of AIOM and
SIAPEC-IAP. The publication of this list provides to both patients
and physicians the possibility to choose among a wide number of
certified laboratories that are localized in different regions and that
are able to provide KRAS mutational testing with adequate
quality.
This first Italian KRAS quality assessment did not reveal
difference in the ability to detect mutations between the techniques
used by the different laboratories. However, it must be emphasized
that CRC specimens with an high content of tumor cells (.70%)
were selected. Different reports suggest that direct sequencing of
PCR products should not be used when the specimens contains
30% or lower tumor cells [16,17]. Although the majority of CRC
specimens contains high numbers of tumor cells, a low tumor cell
content might occur in mucinous tumors, or following adjuvant
radio-chemotherapy for rectal tumors or in small biopsies.
The results of the Italian quality assessment scheme were
superior as compared with the German program [18]. This latter
external quality assessment program run 7 ring trials between
2008 and 2011, with overall 319 participants. Of these, 90.9%
passed, with a failure rate of 9.1%. However, significant
differences between these programs exist. In the German quality
assessment, 10 samples were sent to each center and the response
was due in 10 working days. In addition, 2 points were assigned for
each sample (1 for the correct genotype and 1 for the specific
mutation) and 1 point was deducted for a maximum of two times
in case of technical failure (failure to extract or to amplify DNA).
The threshold to pass the test was set at 17 points corresponding to
85% of the total score. In contrast, the threshold to pass the Italian
quality control was 100% and technical failure were scored
negatively at the same extent of false-negative or false-positive
results.
More recently, the results of a joined regional assessment round
for KRAS testing in Europe have been reported [19]. The
assessment round included 59 laboratories from eight different
European countries. For each country, one regional scheme
organizer prepared and distributed the samples (n.10) for the
participants of their own country. The samples were centrally
validated by one of two reference laboratories. The results of this
assessment was that only 70% of laboratories correctly identified
the KRAS mutational status in all samples. Genotyping errors
were made by 22% of the laboratories, whereas 8% reported
technical failure. The majority of the genotyping errors were false
positive or false negative results. Mistakes were made using both
commercial kits and in-house validated methods.
Although direct comparison between these different quality
assessment schemes cannot be drawn, we hypothesize that the
educational program of AIOM and SIAPEC with the publication
of guidelines followed by their presentation in a number of
national meetings might have improved mutational testing in Italy.
The Italian external quality assessment scheme was only related to
genotyping, whereas the German and the European programs
included reporting. However, in these latter schemes only
genotyping was scored and, therefore, the outcomes are similar
to the Italian program.
In conclusion, the results of this first Italian quality assessment
for KRAS testing suggest that KRAS mutational analysis is
performed with good quality in the majority of Italian centers.
However, this conclusion is limited by the low number of samples
employed that will be increased in the next external quality
assessment, which will also include samples with low percentage of
tumor cells. The Italian KRAS quality assessment scheme might
represent a model for other national and international societies.
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